2022年国际前列腺癌诊疗一体化现状调查
该调查于2022年初通过网页问卷收集全球300余份有效回复,评估前列腺癌PSMA PET显像与放射配体治疗的临床应用与预期。多数回复来自核医学专科医师,PSMA PET与RLT过去5年分别平均增长50%和82%,未来5年预计中位增长100%。调查认为全球PSMA诊疗一体化应用存在差异,面临放射性药物供应、报销、人员及肿瘤内科医师认同等障碍。
要点
- 83%的回复来自具有丰富PET经验的核医学专科医师。
- 最常用PSMA PET示踪剂为[68Ga]PSMA(32%)和[18F]PSMA-1007(31%)。
- PSMA PET与RLT过去5年平均增长分别为50%和82%,未来5年预计中位增长100%。
核心结论
- 尽管热情高涨,该调查显示全球PSMA显像与RLT的应用存在差异,将PSMA靶向诊疗一体化整合入个体化医疗需医学界、监管机构与患者倡导组织共同应对多项挑战。
研究设计与样本
- 该研究为2022年初收集的国际性网页问卷调查,共收到并评估300余份有效回复,问卷覆盖PET显像、临床价值链及RLT应用等特定领域。
主要发现
- 大多数回复(83%)来自具有丰富PET经验的核医学专科医师。
- 在22%的站点,前列腺癌在癌种特异性PET适应证中排名「首位」,平均占所有病例的15%、中位占10%。
- 最常用的PSMA PET示踪剂为[68Ga]PSMA(32%)和[18F]PSMA-1007(31%)。
- 使用者报告过去5年PSMA PET与RLT分别平均增长50%和82%,未来5年预计中位增长100%。
- 更多受访者表示了解个体化剂量学,而非实际常规使用;未来增长最常见的障碍为放射性药物供应、报销、人员可用性及肿瘤内科医师的认同。
关键数值与推荐
- 在22%的站点,前列腺癌在癌种特异性PET适应证中排名「首位」,平均占所有病例的15%、中位占10%。
- 最常用的PSMA PET示踪剂为[68Ga]PSMA(32%)和[18F]PSMA-1007(31%)。
- 过去5年PSMA PET平均增长50%、RLT平均增长82%,未来5年预计中位增长100%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Growing interest in PSMA imaging using [68Ga]- or [18F]-labeled ligands and PSMA-based radioligand therapy (RLT) of prostate cancer (PCa) prompted us to survey the global community on their experiences and expectations. Methods: A web-based survey was composed to interrogate areas specific to PET imaging, the clinical value chain, and RLT applications. International responses were collected in early 2022. In total, over 300 valid responses were received and evaluated. Results: Most responses (83%) were given by nuclear medicine specialists with extensive experience in PET. At 22% of sites, PCa ranked "top" in cancer-type-specific PET indications, with an average and median of 15% and 10% of all cases, respectively. The most frequently used PSMA PET tracers were [68Ga]PSMA (32%) and [18F]PSMA-1007 (31%). Users reported a steady growth in PSMA PET and RLT over the past 5 y, averaging 50% and 82%, respectively, with a further 100% median growth projected over the next 5 y. Of note, more respondents indicated cognizance of personalized dosimetry than actually used it routinely. The most commonly identified barriers to future growth in PCa theranostics were radiopharmaceutical supply, reimbursement, staff availability, and buy-in of medical oncologists. Conclusion: Despite enthusiasm, this survey indicates variable adoption of PSMA imaging and RLT globally. Several challenges need to be addressed by the medical community, authorities, and patient advocacy groups in integrating PSMA-targeted theranostics into personalized medicine.
引用
- Beyer T, Czernin J, Freudenberg L, et al. A 2022 International Survey on the Status of Prostate Cancer Theranostics. J Nucl Med. 2022. PMID: 35953304. doi:10.2967/jnumed.122.264298
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。